Antinociceptive effects of the selective CB2 agonist MT178 in inflammatory and chronic rodent pain models

Pain

Volumn 154, Issue 6, 2013, Pages 864-873

  Vincenzi, Fabrizio ^a   Targa, Martina ^a   Corciulo, Carmen ^a   Tabrizi, Mojgan Aghazadeh ^a   Merighi, Stefania ^a   Gessi, Stefania ^a   Saponaro, Giulia ^a   Baraldi, Pier Giovanni ^a   Borea, Pier Andrea ^a   Varani, Katia ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Analgesia; Dorsal root ganglia; Inflammatory and chronic pain; MT178; Rodent

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANTINOCICEPTIVE AGENT; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MT 178; N ADAMANTYL 3 ETHYL 3,7 DIHYDRO 7 OXO 10 (PYRROLIDIN 1 YL) 2H [1,4]OXAZINO[2,3,4 IJ]QUINOLINE 6 CARBOXAMIDE; SUBSTANCE P; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CHRONIC PAIN; CONTROLLED STUDY; DOSE RESPONSE; DRUG COMPETITION; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY PAIN; MALE; NONHUMAN; PRIORITY JOURNAL;

EID: 84878014862     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1016/j.pain.2013.02.007     Document Type: Article

References (60)

1. F.V. Abbott, K.B. Franklin, and R.F. Westbrook The formalin test: scoring properties of the first and second phases of the pain response in rats PAIN® 60 1995 91 102
2. 2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons PAIN® 138 2008 667 680
3. J.C. Ashton, and E.D. Milligan Cannabinoids for the treatment of neuropathic pain: clinical evidence Curr Opin Investig Drugs 9 2008 65 75
4. 2: a cannabinoid receptor with an identity crisis Br J Pharmacol 160 2010 467 479
5. 2 cannabinoid receptor ligands: structural investigations around a novel class of full agonists J Med Chem 55 2012 6608 6623
6. G. Barbara, B. Wang, V. Stanghellini, R. de Giorgio, C. Cremon, G. Di Nardo, M. Trevisani, B. Campi, P. Geppetti, M. Tonini, N.W. Bunnett, D. Grundy, and R. Corinaldesi Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome Gastroenterology 132 2007 26 37
7. 2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms Eur J Neurosci 23 2006 1530 1538
8. 2 receptors in human brain inflammation Br J Pharmacol 153 2008 277 285
9. 3H]d-aspartate release and changes in glutamate receptor expression in the hippocampus of the mnd mouse J Neurosci Res 90 2012 1148 1158
10. B. Bosier, G.G. Muccioli, E. Hermans, and D.M. Lambert Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities Biochem Pharmacol 80 2010 1 12
11. M. Bujalska Effect of cannabinoid receptor agonists on streptozotocin-induced hyperalgesia in diabetic neuropathy Pharmacology 82 2008 193 200
12. 2 receptors in the brain: role in central immune function Br J Pharmacol 153 2008 240 251
13. A receptor agonist muscimol acts preferentially through forebrain high-affinity binding sites Neuropsychopharmacology 35 2010 999 1007
14. R.E. Coleman Clinical features of metastatic bone disease and risk of skeletal morbidity Clin Cancer Res 12 2006 6243 6249
15. J.H. Cui, W.M. Kim, H.G. Lee, Y.O. Kim, C.M. Kim, and M.H. Yoon Antinociceptive effect of intrathecal cannabinoid receptor agonist WIN 55,212-2 in a rat bone tumor pain model Neurosci Lett 493 2011 67 71
16. 2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain Br J Pharmacol 160 2010 561 573
17. A. Dyson, M. Peacock, A. Chen, J.P. Courade, M. Yaqoob, A. Groarke, C. Brain, Y. Loong, and A. Fox Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat PAIN® 116 2005 129 137
18. V. Di Marzo Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight Nat Neurosci 14 2011 9 15
19. V. Di Marzo Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7 2008 438 455
20. V. Di Marzo, M. Bifulco, and L. De Petrocellis The endocannabinoid system and its therapeutic exploitation Nat Rev Drug Discov 3 2004 771 784
21. 2 receptors Mol Pharmacol 48 1995 443 450
22. A. Fox, A. Kesingland, C. Gentry, K. McNair, S. Patel, L. Urban, and I. James The role of central and peripheral cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain PAIN® 92 2001 91 100
23. J. Guindon, and A.G. Hohmann Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain Br J Pharmacol 153 2008 319 334
24. M.R. Jafari, S. Golmohammadi, F. Ghiasvand, M.R. Zarrindast, and B. Djahanguiri Influence of nicotinic receptor modulators on CB2 cannabinoid receptor agonist (JWH133)-induced antinociception in mice Behav Pharmacol 18 2007 691 697
25. 2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages Cardiovasc Res 84 2009 378 386
26. L. Hanus, A. Breuer, S. Tchilibon, S. Shiloah, D. Goldenberg, M. Horowitz, R.G. Pertwee, R.A. Ross, R. Mechoulam, and E. Fride HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor Proc Natl Acad Sci USA 96 1999 14228 14233
27. T.J. Harrigan, I.F. Abdullaev, D. Jourd'heuil, and A.A. Mongin Activation of microglia with zymosan promotes excitatory amino acid release via volume-regulated anion channels: the role of NADPH oxidases J Neurochem 106 2008 2449 2462
28. A.C. Howlett, F. Barth, T.I. Bonner, G. Cabral, P. Casellas, W.A. Devane, C.C. Felder, M. Herkenham, K. Mackie, B.R. Martin, R. Mechoulam, and R.G. Pertwee International union of pharmacology. XXVII. Classification of cannabinoid receptors Pharmacol Rev 54 2002 161 202
29. G.C. Hsieh, M. Pai, P. Chandran, B.A. Hooker, C.Z. Zhu, A.K. Salyers, E.J. Wensink, C. Zhan, W.A. Carroll, M.J. Dart, B.B. Yao, P. Honore, and M.D. Meyer Central and peripheral sites of action for CB2 receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats Br J Pharmacol 162 2011 428 440
30. E.A. Kowaluk, J. Mikusa, C.T. Wismer, C.Z. Zhu, E. Schweitzer, J.J. Lynch, C.H. Lee, M. Jiang, S.S. Bhagwat, A. Gomtsyan, J. McKie, B.F. Cox, J. Polakowski, G. Reinhart, M. Williams, and M.F. Jarvis ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine) , a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat J Pharmacol Exp Ther 295 2000 1165 1174
31. F.R. Kreitzer, and N. Stella The therapeutic potential of novel cannabinoid receptors Pharmacol Ther 122 2009 83 96
32. A.N. Lozano-Ondoua, C. Wright, A. Vardanyan, T. King, T.M. Largent-Milnes, M. Nelson, J.M. Jimenez-Andrade, P.W. Mantyh, and T.W. Vanderah A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss Life Sci 86 2010 646 653
33. K. Mackie Cannabinoid receptors as therapeutic targets Annu Rev Pharmacol Toxicol 46 2006 101 122
34. D. Malec, M. Mandryk, and S. Fidecka Interaction of memantine and ketamine in morphine- and pentazocine-induced antinociception in mice Pharmacol Rep 60 2008 149 155
35. S.J. Medhurst, K. Walker, M. Bowes, B.L. Kidd, M. Glatt, M. Muller, M. Hattenberger, J. Vaxelaire, T. O'Reilly, G. Wotherspoon, J. Winter, J. Green, and L. Urban A rat model of bone cancer pain PAIN® 96 2002 129 140
36. S. Merighi, S. Gessi, K. Varani, C. Simioni, D. Fazzi, P. Mirandola, and P.A. Borea Cannabinoid CB(2) receptors modulate ERK-1/2 kinase signalling and NO release in microglial cells stimulated with bacterial lipopolysaccharide Br J Pharmacol 165 2012 1773 1788
37. 2 receptors Biochem Pharmacol 79 2010 471 477
38. K.E. Miller, E.M. Hoffman, M. Sutharshan, and R. Schechter Glutamate pharmacology and metabolism in peripheral primary afferents: physiological and pathophysiological mechanisms Pharmacol Ther 130 2011 283 309
39. L.K. Miller, and L.A. Devi The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications Pharmacol Rev 63 2011 461 470
40. E. Niederberger, and G. Geisslinger The IKK-NF-kappaB pathway: a source for novel molecular drug targets in pain therapy? FASEB J 22 2008 3432 3442
41. K. Oshita, A. Inoue, H.B. Tang, Y. Nakata, M. Kawamoto, and O. Yuge CB(1) cannabinoid receptor stimulation modulates transient receptor potential vanilloid receptor 1 activities in calcium influx and substance P Release in cultured rat dorsal root ganglion cells J Pharmacol Sci 97 2005 377 385
42. K.D. Patel, J.S. Davison, Q.J. Pittman, and K.A. Sharkey Cannabinoid CB(2) receptors in health and disease Curr Med Chem 17 2010 1393 1410
43. 2 Pharmacol Rev 62 2010 588 631
44. E.J. Rahn, and A.G. Hohmann Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside Neurotherapeutics 6 2009 713 737
45. 1 cannabinoid receptor: biochemical and pharmacological characterization J Pharmacol Exp Ther 310 2004 905 914
46. 3H]-d-aspartate from primary astrocyte cultures in response to raised external potassium J Neurosci 16 1996 7803 7811
47. E.M. Sánchez Robles, A. Bagües Arias, and M.I. Martín Fontelles Cannabinoids and muscular pain. Effectiveness of the local administration in rat Eur J Pain 16 2012 1116 1127
48. K.A. Simao da Silva, A.F. Paszcuk, G.F. Passos, E.S. Silva, A.F. Bento, F.C. Meotti, and J.B. Calixto Activation of cannabinoid receptors by the pentacyclic triterpene α,β-amyrin inhibits inflammatory and neuropathic persistent pain in mice PAIN® 152 2011 1872 1887
49. K.A. Sluka, M.P. Price, N.M. Breese, C.L. Stucky, J.A. Wemmie, and M.J. Welsh Chronic hyperalgesia induced by repeated acid injections in muscle is abolished by the loss of ASIC3, but not ASIC1 PAIN® 106 2003 229 239
50. E.F. Solomayer, I.J. Diel, G.C. Meyberg, C. Gollan, and G. Bastert Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis Breast Cancer Res Treat 59 2000 271 278
51. T. Sun, W.G. Song, Z.J. Fu, Z.H. Liu, Y.M. Liu, and S.L. Yao Alleviation of neuropathic pain by intrathecal injection of antisense oligonucleotides to p65 subunit of NF-kappaB Br J Anaesth 97 2006 553 558
52. H.B. Tang, Y.S. Li, and Y. Nakata The release of substance P from cultured dorsal root ganglion neurons requires the non-neuronal cells around these neurons J Pharmacol Sci 105 2007 264 271
53. 3 receptors are overexpressed in pleura from patients with mesothelioma and reduce cell growth via Akt/nuclear factor-κB pathway Am J Respir Crit Care Med 183 2011 522 530
54. 3 adenosine receptors Mol Pharmacol 57 2000 968 975
55. G. Vera, V. López-Miranda, E. Herradón, M.I. Martín, and R. Abalo Characterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabetes Pharmacol Biochem Behav 102 2012 335 343
56. 2 receptor agonists Curr Med Chem 14 2007 917 936
57. H. Yamamoto, Y. Shimoshige, T. Yamaji, N. Murai, T. Aoki, and N. Matsuoka Pharmacological characterization of standard analgesics on mechanical allodynia in streptozotocin-induced diabetic rats Neuropharmacology 57 2009 403 408
58. J.Y. Yan, R.Q. Sun, M.G. Hughes, D.J. McAdoo, and W.D. Willis Intradermal injection of capsaicin induces acute substance P release from rat spinal cord dorsal horn Neurosci Lett 410 2006 183 186
59. S. Yoshihara, H. Morimoto, Y. Yamada, T. Abe, and O. Arisaka Cannabinoid receptor agonists inhibit sensory nerve activation in guinea pig airways Am J Respir Crit Care Med 170 2004 941 946
60. M. Zimmermann Ethical guidelines for investigations of experimental pain in conscious animals PAIN® 16 1983 109 110